← Eichor
Study identifier: NCT06304857 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

Condition: Breast Cancer · Heart Failure  ·  Sponsor: 4th Military Clinical Hospital with Polyclinic, Poland

PhasePhase 3
Planned participants188
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Bartosz Krakowiak, PhD, MD  ·  +48 261 660 234  ·  bkrakowiak@4wsk.pl

Always discuss trial participation with your own doctor first.

Locations (3)

4th Military Clinical Hospital with PolyclinicWroclaw, Lower Silesian Voivodeship, PolandRecruiting
Lower Silesian Centre for Oncology, Lung Diseases and HematologyWroclaw, Lower Silesian Voivodeship, PolandRecruiting
Military Medical InstituteWarsaw, Masovian Voivodeship, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06304857